Platelet-Rich Plasma Attenuates 30-kDa Fibronectin Fragment-Induced Chemokine and Matrix Metalloproteinase Expression by Meniscocytes and Articular Chondrocytes

Citation for published version:

Digital Object Identifier (DOI):
10.1177/0363546515597489

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
American Journal of Sports Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Platelet-Rich Plasma Attenuates 30 kDa Fibronectin Fragment Induced Chemokine and MMP Expression by Meniscocytes and Articular Chondrocytes
Abstract

Background: Proteolytic fragments of fibronectin have catabolic effects on cartilage and menisci. Platelet-rich plasma (PRP) is increasingly being used in treatment of a range of joint pathologies but it is unknown whether PRP influences fibronectin fragment (FN-f) pro-catabolic activity.

Hypotheses: The pro-catabolic activity of FN-f on meniscocytes and articular chondrocytes is attenuated by co-treatment with PRP.

Study Design: Controlled laboratory study.

Methods: Human meniscocytes were treated with FN-f (30 kDa) with/without PRP co-incubation and gene expression analyzed by cDNA microarray analysis. Validation of altered expression of known and novel chemokine and protease genes was undertaken by real-time PCR in articular chondrocytes and meniscocytes. Chemokine release was assayed by ELISA and intracellular pathway signaling was evaluated by western immunoblotting.

Results: Microarray analysis and RT-PCR showed increased expression of MMP1,
MMP2, MMP3, MMP9, MMP13, IL-6 and IL-8 (CXCL8), CCL5, CCL20 and CXCL10 chemokines in meniscocytes following treatment with FN-f. Upregulation of these genes was significantly attenuated by PRP. Similar results were seen with articular chondrocytes although no change in MMP2 or MMP9 levels were identified. PRP induced suppression of gene expression was associated with activation of Akt and p44/p42.

Conclusions: 30 kDa FN-f induced expression of a range of pro-inflammatory chemokines and MMPs including IL-8, IL-6, CCL20, CCL5, CXCL10, MMP1, MMP3 and MMP13 by both meniscocytes and articular chondrocytes is attenuated by PRP treatment.

Clinical Relevance: These observations provide support for the use and further trials of PRP in management of cartilage and meniscal injuries.

Keywords: platelet-rich plasma; fibronectin fragment; chondrocyte; chemokine; matrix metalloproteinase
What is known about the subject:

Proteolytic fragments of fibronectin are released from articular cartilage following impact injury and are increased in synovial fluid of patients with osteoarthritis (OA). These fibronectin fragments (FN-f) have catabolic activity inducing expression of a range of inflammatory mediators and proteases that contribute to both cartilage and meniscus degeneration. Removal of FN-f from OA synovial fluid decreases detrimental indicating that targeting these molecules may be of benefit in attenuating the development or progression of cartilage and meniscal pathology. There is increasing interest and application of platelet-rich plasma (PRP) for the treatment of osteoarthritis and a range of other joint and musculoskeletal conditions. PRP is a key source of molecules involved in tissue repair and regeneration and can deliver a variety of bioactive molecules that have the potential to suppress pro-inflammatory and proteolytic pathways. It is however not known whether PRP acts to inhibit the broad range of recognized and novel inflammatory and proteolytic pathways activated by FN-f in human meniscocytes and articular chondrocytes.
What this study adds to existing knowledge:

In addition to confirming recent observations that FN-f increase expression of a range of matrix metallproteinases and chemokines in meniscocytes and articular chondrocytes we have, for the first time, identified that FN-f also increase expression of MMP9 and CCL5, CCL20 and CXCL10 chemokines in human meniscocytes. Co-stimulation of both meniscocytes and articular chondrocytes with PRP significantly attenuated the FN-f increased expression of chemokines and MMPs providing mechanistic support for the use of intra-articular PRP injection for the treatment of degenerative and traumatic joint conditions including OA.
Introduction

Fibronectin (FN) is a multidomain glycoprotein present in most extracellular matrices (ECM), including cartilage and synovium, as a dimeric glycoprotein. The dimeric glycoprotein is formed through a pair of anti-parallel disulfide bonds at the C terminus linking single glycoproteins with a molecular weight of 230–270 kDa. FN isoforms in adult cartilage are significantly different from fibronectins in other tissues and include predominantly the cartilage specific (V + C) isoform (50-80%) with smaller amounts of the of ED-B (+) isoform. Intact FN has important roles in matrix assembly, morphogenesis, cell migration and inflammation through the binding of multiple domains to itself and a range of matrix proteins and cell surface receptors including collagen, fibulin-1, syndecan and integrins. α5β1 integrin is the major FN receptor expressed by articular chondrocytes and has important roles in regulating chondrocyte responses to mechanical loading.

FN levels are elevated in cartilage in osteoarthritis (OA) as a result of increased production and retention. This increase of FN in OA cartilage is associated with an
increase in FN levels in synovial fluid.\textsuperscript{48} As well as being increased in amount, the FN in OA cartilage and synovium is fragmented, comprising FN-fragments (FN-f) of 30–200 kDa.\textsuperscript{22} Unlike intact FN these FN-f have catabolic activity.\textsuperscript{21} FN-f bind to and penetrate cartilage tissue resulting in proteinase expression and cartilage damage.\textsuperscript{60}

FN-f show potent catabolic activity increasing expression of Toll-like receptors and inflammatory cytokines including TNF-\(\alpha\), IL-1\(\beta\), and IL-1\(\alpha\), elevating production of matrix metalloproteinase (MMP) proteases, and suppressing proteoglycan synthesis.\textsuperscript{13, 19, 20, 49, 51} FN-f are also released from articular cartilage following impact injury\textsuperscript{7}, and have been shown to increase production of MMPs by normal and OA meniscocytes in vitro\textsuperscript{50}, indicating that a general increase in levels of these biologically active fragments in synovial fluid in OA or other joint pathologies is also detrimental to meniscus structure and function.

Removal of FN-f from OA synovial fluid has been shown to diminish detrimental effects on cartilage\textsuperscript{22} indicating that targeting these molecules may be of benefit in attenuating the development or progression of cartilage and meniscal pathology. A
specific pharmacological agent that inhibits the catabolic effects of FN-f has not yet been developed but there is increasing interest in the use of biological therapies such as hyaluronan (HA) and platelet-rich plasma (PRP) for the treatment of osteoarthritis and a range of other joint and musculoskeletal conditions.\textsuperscript{15, 28, 29, 31, 38}

PRP is a key source of molecules involved in tissue repair and regeneration and can deliver a variety of bioactive molecules. These include a number of growth factors recognized to be important in regulation of chondrocyte proliferation and anabolic function including platelet-derived growth factor, transforming growth factor beta, fibroblast growth factor and insulin-like growth factor 1.\textsuperscript{5, 56} Delivery of a cocktail of agents, as is present in PRP, would be expected to be beneficial for repair of cartilage and meniscus injury and enhance tissue repair by stimulation of anabolic activity whilst proinflammatory and catabolic pathways would be inhibited.\textsuperscript{2, 26, 53}

The aim of this study was to assess whether PRP has inhibitory effects on expression of pro-inflammatory and proteolytic molecules induced by FN-f in human meniscocytes and articular chondrocytes.
Materials and Methods

Human articular chondrocyte and meniscocyte isolation and culture

Human cartilage and meniscus samples were obtained from surgical discard tissue, with consent (TMU-JIRB No.201305003), at knee joint arthroplasty from patients with OA (n = 43, mean age 72.86 years, range 56-84 years). Residual OA cartilage with predominantly grade II and III lesions (Collins/McElligot system) from each joint was removed and pooled. Cartilage and meniscus tissue were cut into small fragments, incubated with antimicrobial solution, containing 500 IU/mL penicillin (Gibco, Invitrogen, Burlington, Ontario, Canada), 500 mg/mL streptomycin (Gibco) and 2.5 μg/mL Fungizone (Sigma, St Louis, MO, USA) for 4 h, and then washed with sterile phosphate-buffered saline (PBS) before digestion. Cells were extracted by sequential enzymatic digestion with 0.25% trypsin (Gibco) and collagenase type H (Sigma). Extracted cells were re-suspended in 10 mL Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 HAM medium (Gibco) supplemented with 10% FBS (Gibco), 100 I.U./mL penicillin and 100 mg/mL streptomycin; seeded in complete
medium at a density of $5 \times 10^5$ cell/mL in 60 mm Petri dishes (TPP, Trasadingen, Switzerland); and cultured in a humidified 5% CO$_2$ incubator at 37°C for further experimental procedures. Cells between passages 3 and 5 were used.

**Experimental protocol**

Human articular chondrocytes and meniscocytes were seeded at $5 \times 10^5$ cells/dish and grown as a monolayer for 5 days in 60 mm tissue culture Petri dishes. Cells were washed with sterile PBS twice, placed in serum-free media for 2 hours, and then co-incubated with fibronectin proteolytic fragments 30 kDa at a concentration of 0.5 μg/mL for 24 hours. Freeze-dried powder of PRP was prepared by Regen Lab and Regenkit (Regen Lab, Lausanne, Switzerland) by centrifugation of peripheral blood, using a thixotropic gel for cell separation and citrate as anticoagulant. The obtained PRP was approximately 3.3-fold platelet increase above baseline. Each ampoule of PRP was dissolved with 1 mL of distilled water. The concentrations of two major growth factors were - transforming growth factor-beta1 (TGF-β1) 125.9 pg/mL and platelet-derived growth factor (PDGF) 40.8 pg/mL. 80 μL of PRP solution was added
to cells with 2 mL medium to yield a final concentration of TGF-β1 5.036 pg/mL and PDGF 1.632 pg/mL.

Extraction of RNA and Real-Time Polymerase Chain Reaction

Total RNA was extracted using TRIzol® RNA Isolation Reagents (Invitrogen, NY, USA). For first-strand cDNA synthesis, 2 μg total RNA was used in a single-round reverse-transcription reaction by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). qPCR reactions were carried out in a final volume of 20 μL containing 1 μL of 20X TaqMan® Gene Expression Assay probe (Applied Biosystems), 10 μL of 2X TaqMan® Gene Expression Master Mix, 5 μL of RNase-free water, and 4 μL of cDNA. Complement DNAs were amplified with the following condition: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds, using a ViiA7 real-time PCR system (Applied Biosystems). Resultant cycle threshold (Ct) values were normalized to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and analyzed using the
148 $2^{-\Delta\Delta Ct}$ method. The Taqman Probes used for gene expression studies are listed in Table 1.

150 **Microarray assay and data analysis**

151 RNA was extracted from control and cells incubated with 30 kDa FN-γ. 0.2 μg of total RNA was amplified by a Low Input Quick-Amp Labeling kit (Agilent Technologies, Palo Alto, CA, USA) and labeled with Cy3 (Agilent Technologies). 0.6 μg of Cy3-labeled cRNA was fragmented to an average size of 50-100 nucleotides by incubation with fragmentation buffer at 60°C for 30 minutes. Correspondingly fragmented labeled cRNA is then pooled and hybridized to Agilent SurePrint G3 Human V2 GE 8×60K Microarray (Agilent Technologies) at 65°C for 17 h. After washing and drying by nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner at 535 nm. Scanned images are analyzed by Feature extraction10.5.1.1 software (Agilent Technologies). The microarray data comply with MIAME (Minimum Information About a Microarray Experiment) guidelines, and the raw data have been deposited in a MIAME-compliant database.
Protein Extraction and Western blotting

Following stimulation cells were immediately washed with ice-cold PBS and protein extracted with standard lysis buffer at 4°C for 15 min. Whole-cell lysates were collected after centrifugation at 13,000 rpm for 10 min. Equal amounts of protein were loaded onto 10% SDS-polyacrylamide gel and following electrophoresis were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Membranes were blocked overnight at 4°C with 2% BSA in TBST (12.5 mM Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20). After washing with TBST, blots were incubated at 4°C overnight with primary antibodies (PathScan® Multiplex Western Cocktail I 1/1000; p44/42 MAPK 1/1000; AKT 1/1000) (all from Cell Signaling Technology, MA, USA) diluted in TBST respectively, washed 6 times before incubation with HRP-labeled secondary antibody 1/5000 (DakoCytomation, Copenhagen, Denmark) for 1 h at room temperature. Membranes were rewashed extensively and antibody binding was visualized with Immobilon™ Western HRP Substrate (Millipore). Immunoblots were scanned by a UVP BioSpectrum AC image system (UVP, Upland, CA, USA) and
quantitated using VisionWork LS software (UVP). Anti-alpha-tubulin (1/5000; Abcam, Cambridge, UK) acted as internal control.

ELISA

Quantification of IL-8 (CXCL8) in supernatants of cultured medium was carried out using Quantikine ELISA kits (R&D Systems, Minneapolis, USA).

Statistical analysis

The values were expressed as fold of band intensity of the target gene or protein to the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene or alpha-tubulin. The results are expressed as the mean ± SD. Data are analyzed using SPSS (Statistical Package for Social Sciences) statistical software 18.0; all statistical tests use Student's t-test, and the p value < 0.05 is considered statistically significant.
Results

PRP attenuates FN-f induced chemokine gene expression in meniscocytes and articular chondrocytes

Microarray analysis

To investigate the global gene change in meniscocytes as a result of stimulation with 0.5 μg/mL 30 kDa FN-f an initial microarray assay was carried out. Analysis using the GeneSpring GX software showed that expression of 258 genes was significantly altered. Novel findings were the upregulation of several chemokine genes. The top 5 upregulated genes were IL-8 (CXCL8), CCL20, IL-6, CXCL10, and CCL5, respectively (Table 2). To assess whether PRP had any effect on the 30 kDa FN-f induced changes in gene expression meniscocytes were co-incubated with PRP and 30 kDa FN-f. With co-incubation there was a significant downregulation of expression of each of these top 5 upregulated genes rather than the increased expression seen with FN-f treatment alone (Table 2).

Quantitative gene expression
To confirm these results and to establish whether similar effects were seen in articular chondrocytes experiments were undertaken in which changes in gene expression were assessed by Q-PCR. Following 24 hours incubation with 30 kDa FN-f expression of IL-8 (410.1 ± 310.9 fold), CCL20 (287.8 ± 50.3 fold), IL-6 (281.0 ± 199.4 fold), CXCL10 (859.9 ± 665.2 fold), and CCL5 (167.7 ± 90.4 fold) was significantly increased in meniscocytes. These changes were attenuated by co-treatment with PRP for each of the 5 genes: IL-8 (18.1 ± 13.7 fold, p = 0.042); CCL20 (14.5 ± 11.5 fold, p = 0.0008); IL-6 (12.7 ± 7.8 fold, p = 0.0362); CXCL10 (6.2 ± 5.6 fold, p = 0.0448); CCL5 (2.9 ± 2.1 fold, p = 0.011) (Figure 1A). 30 kDa FN-f also significantly upregulated expression of IL-8, CCL20, IL-6, CXCL10, and CCL5 in articular chondrocytes (164.4 ± 78.2 fold, p = 0.0095; 122.6 ± 76.34 fold, p = 0.0014; 43.8 ± 22.9 fold, p = 0.033; 186.7 ± 140.4 fold, p = 0.042; 14.29 ± 11.27 fold, p = 0.003, respectively). These changes were significantly attenuated by co-treatment with PRP (IL-8 - 25.3 ± 22.1 fold, p = 0.005; CCL20 - 18.7 ± 9.5 fold, p = 0.0009; IL-6 - 10.7 ± 7.9 fold, p = 0.034; CXCL10 - 8.6 ± 4.9 fold, p = 0.044, and CCL5 - 2.4± 1.9 fold, p =...
With PRP treatment alone there was no significant change in expression of IL-8, CCL20, IL-6, CXCL10, and CCL5 genes in either meniscocytes or articular chondrocytes over the time period tested.

PRP reduces FN-f induced IL-8 secretion by meniscocytes and articular chondrocytes

IL-8 secretion by primary meniscocytes was significantly increased following 30 kDa FN-f stimulation for 24 hours (603.59 ± 594.81 vs 112.8 ± 32.3 pg/mL, p = 0.0037) (Figure 2A). This enhanced production was significantly suppressed by PRP co-incubation (266.38 ± 214.09 pg/mL, p = 0.0087) (Figure 2A). Treatment with PRP alone had no significant effect on basal IL-8 secretion levels (128.37 ± 51.29 vs 112.8 ± 32.3 pg/mL, p = 0.0583). 30 kDa FN-f had similar but more pronounced effects on articular chondrocytes showing a significant increase in IL-8 secretion following stimulation for 24 hours (5672.86 ± 5266.53 vs 155.15 ± 52.37 pg/mL, p = 0.0026).
PRP but remained above basal levels (1049.26 ± 866.66 pg/mL, p = 0.0024) (Figure 2B). There was a small, but non-significant increase in IL-8 levels when articular chondrocytes were incubated with PRP alone (237.14 ± 97.45 vs 155.15 ± 52.37 pg/mL, p = 0.0523).

FN-f induced MMP expression by meniscocytes and articular chondrocytes is inhibited by PRP

Following incubation of meniscocytes with 30 kDa FN-f for 24 hours gene expression of MMP1, MMP2, MMP3, MMP9, and MMP13 was significantly increased (112.7 ± 58.0 fold; 1.9 ± 0.4 fold; 41.7 ± 22.0 fold; 1.7 ± 0.3 fold; 15.6 ± 2.2 fold, respectively). Co-incubation with PRP significantly attenuated the effect of 30 kDa FN-f on MMP1, MMP2, MMP3 and MMP13 gene expression (6.6 ± 4.2 fold; 1.0 ± 0.2 fold; 3.4 ± 2.0 fold; 2.3 ± 1.3 fold, respectively). MMP9 gene expression was also decreased by co-incubation with PRP but the results did not reach statistical significance. There was no change in gene expression of MMP1, MMP2, MMP3, MMP9, and MMP13 in meniscocytes cultured for 24 hours in PRP alone (Figure 3A).
Articular chondrocyte expression of MMP1, MMP3 and MMP13 genes was significantly upregulated by incubation with 30 kDa FN-f (17.6 ± 11.3 fold; 29.2 ± 18.3 folds; 6.3 ± 5.7 fold, respectively). This effect was significantly attenuated by co-treatment with PRP (3.4 ± 1.9 fold; 4.3 ± 3.1 fold; 2.4 ± 0.6 fold, respectively). In contrast to meniscocytes, MMP2 and MMP9 genes expression was not upregulated by 30 kDa FN-f stimulation. MMP1, 2, 3, 9, and 13 showed no significant gene regulation following PRP treatment alone (Figure 3B).

Akt and p44/42 MAP kinase phosphorylation induced by PRP

To investigate potential mechanisms by which PRP may be influencing chemokine and MMP gene expression we looked at the activation of Akt and p44/42 MAP kinase, both molecules being recognized as important regulatory intracellular signaling pathways in chondrocytes and meniscocytes. Following stimulation with PRP Akt phosphorylation was rapidly increased in meniscocytes and maintained for up to 3 hours (16.63 ± 5.28 fold, p = 0.0096 at 0.5 h; 10.47 ± 1.94 fold, p = 0.0023 at 1 h; 4.74 ± 2.42 fold, p = 0.0533 at 3 h; compared to baseline). p44/42 phosphorylation was similarly increased
over the same time course (5.24 ± 1.23 fold, p = 0.0015 at 0.5 h; 3.66 ± 0.95 fold, p = 0.0033 at 1 h; 4.54 ± 2.29 fold, p = 0.0258 at 3 h, compared to baseline). Under identical conditions similar results were seen when articular chondrocytes were incubated with PRP (Figure 4). Phosphorylation of Akt was increased at each time point (0.5 h = 19.01 ± 5.30 fold, p = 0.0016; 1 h = 21.26 ± 4.45 fold, p = 0.0005; 3 h = 12.47 ± 5.91 fold, p = 0.0122, compared to baseline). Phosphorylation of p44/42 MAP kinase followed an analogous pattern (0.5 h = 3.58 ± 2.06 fold, p = 0.0487, 1 h = 3.33 ± 2.62 fold, p = 0.1175, 3 h = 2.67 ± 2.47 fold, p = 0.204, compared to baseline).
In this study we aimed to assess the influence of PRP on FN-f induced pro-inflammatory and proteolytic activity of human meniscocytes and articular chondrocytes. Using a gene microarray we have identified that 30-kDa FN-f induces increased gene expression of several chemokines in meniscocytes and chondrocytes. In addition to confirming observations that FN-f increases expression of MMP1, MMP2, MMP3, MMP13, IL-6 and IL-8 in meniscocytes we have, for the first time, identified that FN-f also increases expression of MMP9 and CCL5, CCL20 and CXCL10 chemokines in human meniscocytes. Similar effects are evident in articular chondrocytes although we found no change in MMP2 or MMP9 expression in these cells consistent with findings by others. Importantly, co-stimulation of both meniscocytes and articular chondrocytes with PRP significantly attenuated the FN-f increased expression of chemokines and MMPs.

Currently 44 human chemokine ligands 21 chemokine receptors have been described. Chemokine receptors contain 7 transmembrane domains and are G protein-coupled.
Whilst chemokines act as critical extracellular mediators of cell migration, particularly in the immune system there is increasing interest in potential roles as inflammatory mediators in joint tissues. Chondrocytes and meniscocytes express numerous CC and CXC chemokines, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL11 (eotaxin-1), CXCL1, CXCL2, CXCL3, IL-8 (CXCL8), in addition to a number of chemokine receptors which potentially play important roles in activating catabolic pathways. The pattern of chemokine and chemokine receptor expression in normal and OA chondrocytes suggests that chemokines have an impact in cartilage homeostasis and release of matrix-degrading enzymes in normal cartilage remodeling and cartilage breakdown. Chemokine levels are increased in synovial fluid in patients with osteoarthritis. Chemokine and chemokine receptor expression is also elevated in damaged menisci, indicating that chemokine production in cartilage or meniscus due to biomechanical injury is important in the development of degenerative joint disease. Our observation that meniscocytes, in addition to chondrocytes, express CCL5, CCL20 and CXCL10 chemokines and that expression of these cytokines is increased in
articular chondrocytes and meniscocytes on exposure to the proinflammatory 30 kDa FN-f is novel. The effect of increased expression of these chemokines in cartilage and menisci is not yet clear. Whilst IL-1β and high-mobility group protein 1 (HMGB1) increase expression of CCL5, CCL20 and CXCL10 chemokines in human chondrocytes, expression of CCL5 is decreased by the chondroprotective cytokine IL-4 indicating likely roles as pro-inflammatory mediators in the OA. Cartilage breakdown results in production of metabolically active breakdown products such as FN-f. It is likely, although not yet confirmed that FN-f can also be produced in menisci following acute or chronic degeneration and have effects on all intra-articular tissues. Meniscocytes express a range of MMPs including MMP1, MMP2, MMP3, MMP8, MMP9 and MMP13. Levels of MMPs in synovial fluid are elevated rapidly in patients with a meniscal injury and remain elevated for at least 20 years post injury. Targeting MMP activity within the joint may prevent long-term damage. Pro-catabolic FN-fs appear to act predominantly through the α5β1 integrin receptor. Thus, it would be possible to attempt to influence FN-f activity through targeting this
receptor. However, as single agent therapies are increasingly found to be ineffective there is interest in more broad based biological approaches to treating joint injury and osteoarthritis, especially in its early phase. Targeting pathways activated by FN-f may be an effective means of inhibiting production of multiple mediators of cartilage destruction.43

Autologous PRP injections were first used in 1987 in open heart surgery.14 As a low cost and minimally invasive way to obtain a natural concentration of autologous growth factors, PRP is being studied in different fields of medicine for its ability to aid tissue regeneration.12,16 PRP has been shown to enhance the healing of meniscal defects in a rabbit model.24 Preclinical studies showing that PRP enhances chondrocyte viability, proliferation and matrix production provide mechanistic support for the use of intra-articular PRP injection.25, 36 The optimal concentration, composition and relative importance of each of the components of PRP for clinical use remain unclear. Platelet concentrations of 2.5-3 fold above baseline are considered to be ideal, with higher concentrations potentially inhibiting tissue healing.17, 46, 55 Furthermore the “ideal”
platelet concentration may depend on the target parameter (e.g., direct promotion of
tissue healing or stem cell recruitment), the tissue being treated (e.g., bone, cartilage, or
tendon), and stage of disease or wound healing. Consequently, the “ideal” platelet
concentration for various clinical scenarios remains unknown. PRP concentration can
vary considerably depending on an individual’s blood platelet levels from day to day,
diet, general health, medication and exercise. The method of PRP preparation also
influences platelet concentration and levels of growth factors. PRP used in treatment of
osteoarthritis usually contains between 2-6 fold normal platelet concentrations\(^4\)
although the optimal protocol for PRP injection in knee OA has not been defined. PRP,
approximately 6.8 fold above baseline, inhibits the inflammatory processes in human
osteoarthritic chondrocytes\(^5\) whilst a double-blinded, randomized controlled trial using
PRP with a platelet concentration of approximately 3 fold above baseline showed
benefit over placebo.\(^3\) Other randomized controlled trials have also shown that PRP
injection, although with variable preparation formulae, provides symptomatic relief in
early knee OA\(^3\), a significantly better clinical outcome compared with HA treatment
in grade III gonarthrosis and efficacy in management of pain and inflammation in OA. The commercially available PRP preparation we used had a platelet concentration of 3.3 fold and is within the ‘therapeutic range’. The preparation contained 125.9 and 40.8 pg/mL of TGF-β1 and PDGF respectively which, at the final concentration used in our experimental model system, are at a level at which they would be expected to be biologically active. In the current study the levels of Akt and p44/42 MAP kinase phosphorylation rapidly increase in both meniscocytes and articular chondrocytes upon incubation with PRP. This is in line with the published literature on Akt and p44/42 MAP kinase phosphorylation following incubation of chondrocytes with a range of growth factors and cytokines. We have shown that PRP can attenuate the effects of FN-f on both chondrocyte and meniscocyte production of pro-catabolic chemokines and MMPs. The mechanisms by which these effects are produced are not clear but are likely to be multifactorial as PRP can potentially affect numerous overlapping pathways simultaneously due to the presence of a number of anti-inflammatory cytokines and anabolic growth factors.
Interestingly PRP has been shown to stimulate endogenous HA production and show similar effects to HA in the suppression of inflammatory gene and protein expression in synoviocytes and cartilage. High-molecular-weight (800 kDa) HA is believed to be effective in vitro and in vivo in blocking the catabolic action of FN-f by preventing entry of the fragments into the cartilage. A recent in vitro study comparing the activity of HA and PRP on the expression of anabolic and catabolic genes and inflammatory mediators from human OA cartilage and synoviocytes indicated that whilst both agents decreased catabolic activity, PRP treatment also caused a significant reduction of MMP13, an increase in HAS-2 expression in synoviocytes and an increase in cartilage synthetic activity compared with HA.
Conclusion

In the current study, 30 kDa FN-f induced production of a range of chemokines and MMPs including IL-8, IL-6, CCL20, CCL5, CXCL10, MMP1, MMP3 and MMP13 by both meniscocytes and articular chondrocytes was attenuated by PRP treatment. These observations suggest the mechanism by which PRP might help osteoarthritis and suggests a rationale for continued limited clinical trials. Variations in the composition of PRP from patient to patient are however recognized and composition may also vary depending on the device and protocols used for preparation, methods and time of storage. Due to these limitations and questions remaining on potential interactions with other biologics or materials the current use of PRP in orthopedics needs to be further established.
References


563 60. Xie D, Homandberg GA. Fibronectin fragments bind to and penetrate cartilage tissue resulting in proteinase expression and cartilage damage. *Biochim Biophys Acta.* 1993;1182(2):189-196.

568
Table 1. Taqman Probes used for Gene Expression Studies.

<table>
<thead>
<tr>
<th>GeneSymbol</th>
<th>Accession No.</th>
<th>Applied Biosystems Order No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>NM_000600</td>
<td>Hs00174131_m1</td>
</tr>
<tr>
<td>IL-8</td>
<td>NM_000584</td>
<td>Hs00174103_m1</td>
</tr>
<tr>
<td>CXCL10</td>
<td>NM_001565</td>
<td>Hs00171042_m1</td>
</tr>
<tr>
<td>CCL5</td>
<td>NM_002985</td>
<td>Hs00174575_m1</td>
</tr>
<tr>
<td>CCL20</td>
<td>NM_004591</td>
<td>Hs00355476_m1</td>
</tr>
<tr>
<td>MMP1</td>
<td>NM_002421</td>
<td>Hs00233958_m1</td>
</tr>
<tr>
<td>MMP2</td>
<td>NM_004530</td>
<td>Hs01548727_m1</td>
</tr>
<tr>
<td>MMP3</td>
<td>NM_002422</td>
<td>Hs00968305_m1</td>
</tr>
<tr>
<td>MMP9</td>
<td>NM_004994</td>
<td>Hs00234579_m1</td>
</tr>
<tr>
<td>MMP13</td>
<td>NM_002427</td>
<td>Hs00233992_m1</td>
</tr>
<tr>
<td>GAPDH</td>
<td>NM_002046</td>
<td>Hs02758991_g1</td>
</tr>
</tbody>
</table>

Table 2. Top of 5 upregulated genes (ranking 1-5) by 30 kDa FN-f stimulation and downregulated chemokine genes by PRP treatment in meniscocytes.

<table>
<thead>
<tr>
<th>Upregulated genes</th>
<th>Log Ratio (2)</th>
<th>Downregulated genes</th>
<th>Log Ratio (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranking</td>
<td>GeneSymbol</td>
<td></td>
<td>Ranking</td>
</tr>
<tr>
<td>1</td>
<td>IL-8</td>
<td>9.358</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>CCL20</td>
<td>8.750</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>IL-6</td>
<td>7.563</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>CXCL10</td>
<td>7.412</td>
<td>16</td>
</tr>
<tr>
<td>5</td>
<td>CCL5</td>
<td>6.545</td>
<td>17</td>
</tr>
</tbody>
</table>
Figure legends

Figure 1. Validation of microarray analysis in both (A) meniscocytes and (B) articular chondrocytes. Top 5 upregulated genes including IL-8, CCL20, IL-6, CXCL10, and CCL5 induced by 30 kDa FN-f all showed significant downregulation by the treatment of PRP. (* p < 0.05, compared with control; ** p < 0.01, compared with control; # p<0.05, 30 kDa+PRP vs 30 kDa).

Figure 2. Effects of PRP on 30 kDa FN-f induced IL-8 release. (A) IL-8 release induced by 30 kDa FN-f was suppressed by PRP treatment in meniscocytes. (B) Similar effect was seen in articular chondrocytes. (** p<0.01, compared with control; # p<0.05, 30 kDa+PRP vs 30 kDa).

Figure 3. Effects of PRP on 30 kDa FN-f induced MMP expression in both (A) meniscocytes and (B) articular chondrocytes. Upregulation of MMPs induced by 30 kDa FN-f was suppressed by the treatment of PRP in meniscocytes. In articular chondrocytes MMP1, MMP3, and MMP13 gene expression showed the similar pattern. There was no significant change in MMP2 and MMP9 gene expression in articular chondrocytes. (* p<0.05, compared with control; # p<0.05, 30 kDa+PRP vs 30 kDa).

Figure 4. Protein phosphorylation of Akt and p44/42 by PRP treatment in human meniscocytes (A) and articular chondrocytes (B). Left panel - representative blots; right panel - semiquantitative data. Rapid protein phosphorylation of Akt and p44/42 was recognized in both cell types. (* p<0.05, compared with control; ** p<0.01, compared with control; *** p<0.001, compared with control).